Research Article

Association between Variation of Troponin and Prognosis of Acute Myocardial Infarction before and after Primary Percutaneous Coronary Intervention

Table 2

Characteristics of the △cTnI cohort versus cohort lack of repeated cTnI assessments.

Variables△cTnI cohortCohort lack of repeated cTnI assessments value

N11382448----
Age (years)59(12.31)59(12.08)0.095
Male (%(n))68.5(779)79.0(1934)≤0.001
BMI (kg/m2)25.99(3.76)26.01(7.85)0.917
Heart rate (beats per minute)77.45(36.81)77.84(25.11)0.712
Systolic blood pressure (mmHg)124(40)120(72)0.015
Diastolic blood pressure (mmHg)77(25)71(20)≤0.001
History of PCI (%(n))9.8(111)12.5(306)0.019
History of CABG (%(n))0.9(10)0.8(20)0.845
Hypertension (%(n))59.3(675)59.7(1461)0.855
Hyperlipidemia (%(n))64.9(739)83.5(2043)≤0.001
Smoking (%(n))38.5(438)59.9(1465)≤0.001
Diabetes (%(n))32.2(366)32.6(799)0.561
Total cholesterol (mg/dl)1.37(1.04)2.54(2.05)≤0.001
HDL-cholesterol (mg/dl)3.15(1.82)2.35(2.03)≤0.001
LDL-cholesterol (mg/dl)1.43(1.28)2.35(2.03)≤0.001
Triglycerides (mg/dl)0.96(0.58)1.19(0.97)≤0.001
ALT (IU/L)25.44(5.62)25.99(3.79)0.619
Statin (%(n))65.6(747)88.8(2174)≤0.001
Aspirin (%(n))67.0(762)63.6(1559)0.060
Clopidogrel (%(n))42.9(488)76.8(1879)≤0.001
Ticagrelor (%(n))27.0(307)16.9(414)≤0.001
Warfarin (%(n))0.2(2)0.5(13)0.167
ACEI (%(n))47.6(542)60.0(1469)≤0.001
ARB (%(n))5.9(67)7.1(175)0.174
Beta-blockers (%(n))62.0(706)82.5(2020)≤0.001
Ezetimibe (%(n))1.2(14)0.5(12)0.020
Diuretic (%(n))18.6(212)29.3(719)≤0.001
MACE (%(n))4.1(47)10.0(246)≤0.001
Death (%(n))2.3(26)7.7(189)≤0.001
CV death (%(n))1.2(13)6.4(157)≤0.001
Stroke (%(n))1.5(17)2.1(51)0.292

Continuous data are presented as mean ± SD or median (interquartile range); categorical variables are presented as % (n). PCI, percutaneous coronary intervention; BMI, body mass index; CABG, coronary artery bypass grafting; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride; ALT, alanine aminotransferase; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; MACE, major adverse cardiovascular events; CV death, cardiovascular death.